Activation of AKT by Dox has been linked to the presence of human epidermal growth factor receptor 3 (HER3, ERBB3 ) in ovarian cancer and was attenuated by the addition of tyrosine kinase inhibitors lapatinib and/or erlotinib [45]. Here, AKT1 is linked to ovarian cancer.